Maxim analyst Jason McCarthy upgraded ContraFect to Buy from Hold with a $3 price target. The firm is positive on the company’s opportunity for exebacase in prosthetic joint infections, or PJIs, driven by staphylococcus infections, which it is now factoring into its valuation model. A Phase 1b/2 single-center study in France was initiated on April 3rd, with the first patient expected to be dosed soon, and the company is also going to have several presentations at the ECCMID meeting this weekend, highlighting the potential of exebacase and lysin candidate CF-370 in infections driven by gram-positive and gram-negative bugs, respectively, the analyst tells investors in a research note.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on CFRX:
- ContraFect Announces Multiple Presentations of New Data at the 33rd Annual ECCMID Meeting
- ContraFect announces initiation of Phase 1b/2 study of exebacase
- ContraFect Announces Initiation of a Phase 1b/2 Study of Exebacase in Patients with Chronic Prosthetic Joint Infections of the Knee
- ContraFect Reports Fourth Quarter 2022 and Full Year 2022 Financial Results and Provides Business Update
- ContraFect reports Q4 EPS ($16.14) vs. ($8.95) last year